Centre for Paediatric Pharmacy Research, University College London School of Pharmacy, BMA/Tavistock House Entrance, Mezzanine Floor, London, WC1H 9JP, UK.
Paediatr Drugs. 2013 Jun;15(3):203-15. doi: 10.1007/s40272-013-0030-8.
Medication reconciliation is an important process in reducing medication errors in many countries. Canada, the USA, and UK have incorporated medication reconciliation as a priority area for national patient safety initiatives and goals. The UK national guidance excludes the pediatric population. The aim of this review was to explore the occurrence of medication discrepancies in the pediatric population. The primary objective was to identify studies reporting the rate and clinical significance of the discrepancies and the secondary objective was to ascertain whether any specific interventions have been used for medication reconciliation in pediatric settings. The following electronic bibliographic databases were used to identify studies: PubMed, OVID EMBASE (1980 to 2012 week 1), ISI Web of Science, ISI Biosis, Cumulative Index to Nursing and Allied Health Literature, and OVID International Pharmaceutical Abstracts (1970 to January 2012). Primary studies were identified that observed medication discrepancies in children under 18 years of age upon hospital admission, transfer and discharge, or had reported medication reconciliation interventions. Two independent reviewers screened titles and abstracts for relevant articles and extracted data using pre-defined data fields, including risk of bias assessment. Ten studies were identified with variances in reportage of stage and rate of discrepancies. Studies were heterogeneous in definitions, methods, and patient populations. Most studies related to admissions and reported consistently high rates of discrepancies ranging from 22 to 72.3 % of patients (sample size ranging from 23 to 272). Seven of the studies were low-quality observational studies and three studies were 'grey literature' non-peer reviewed conference abstracts. Studies involving small numbers of patients have shown that medication discrepancies occur at all transitions of care in children. Further research is required to investigate and demonstrate how implementing medication reconciliation can reduce discrepancies and potential patient harm.
药物重整在许多国家都是减少药物错误的重要过程。加拿大、美国和英国已将药物重整纳入国家患者安全计划和目标的优先领域。英国国家指南不包括儿科人群。本研究旨在探讨儿科人群中药物差异的发生情况。主要目的是确定报告差异发生率和临床意义的研究,并确定在儿科环境中是否使用了任何特定的干预措施进行药物重整。使用以下电子书目数据库来确定研究:PubMed、OVID EMBASE(1980 年至 2012 年第 1 周)、ISI Web of Science、ISI Biosis、 Cumulative Index to Nursing and Allied Health Literature 和 OVID International Pharmaceutical Abstracts(1970 年至 2012 年 1 月)。确定了观察儿童在入院、转院和出院时药物差异的原始研究,或报告药物重整干预措施的研究。两名独立评审员筛选了标题和摘要,以确定相关文章,并使用预定义的数据字段提取数据,包括风险评估。有 10 项研究报告了差异的阶段和发生率存在差异。研究在定义、方法和患者人群方面存在差异。大多数研究与入院相关,报告的差异率始终很高,范围为 22%至 72.3%的患者(样本量从 23 到 272)。其中 7 项为低质量观察性研究,3 项为非同行评审会议摘要的“灰色文献”。涉及少量患者的研究表明,药物差异在儿童所有的护理过渡中都存在。需要进一步研究以调查和证明实施药物重整如何减少差异和潜在的患者伤害。